top of page

Our Firm

Founded in 2015

​

To provide expert advice on strategic life sciences transactions to a select number of clients

Expertise

Pharmaceutical and biotech collaborations

Medical device collaborations

Intellectual property licensing

Commercialization agreements

Joint ventures

Asset acquisitions and divestitures

Spinout transactions

M&A due diligence 

Venture capital financing

AstraZeneca

Biogen

Broad Institute

Gilead

Genzyme

Johnson & Johnson and its affiliates

Pfizer

RiverVest Venture Partners

Salient Surgical

Stanford University

Vertex

Yale University

Representative clients
at Sexton Riley LLP and former firm
Representative transactions
at Sexton Riley LLP and former firm

​

  • For Johnson & Johnson and its affiliates:

    • Collaboration with Pharmacyclics for oncology drug IMBRUVICA

    • Collaboration with Legend Biotech for novel CAR-T product CARVYKTI

    • Collaboration agreement with Idorsia, in connection with J&J's $30 billion acquisition of Actelion 

    • Collaboration agreements with Gilead and ViiV Healthcare for HIV drug combination regimens

    • Divestiture of U.S. Nucynta rights to Depomed

    • Acquisition of Aragon Pharmaceuticals, including rights to ERLEADA

    • Remicade and Simponi distribution agreement amendment and settlement with Merck

    • Doxil manufacturing agreement with Ben Venue Laboratories

    • Spinout of and license agreement with Movetis NV

    • Collaboration and license agreement and co-promotion agreements with Millennium Pharmaceuticals (Takeda) for VELCADE

​​

  • For other life sciences clients:

    • Biogen’s acquisition of worldwide rights to TYSABRI from Elan Pharmaceuticals

    • Genzyme's strategic alliance with Alnylam Pharmaceuticals for RNAi therapeutics

    • Alexion’s collaboration agreement with Moderna Therapeutics for messenger RNA therapeutics

    • Agreements for manufacturing and supply, distribution, co-promotion, sponsored research, compound library screening, Rx-to-OTC switches and authorized generics for various pharmaceutical, biotech and medical device companies.

​​

  • Venture capital financings and related transactions for RiverVest Venture Partners and its affiliates, including investments in Smart Wires, Lyric Pharmaceuticals, Smart Wires, Excaliard Pharmaceuticals, Lumena Pharmaceuticals, Tryton Medical, Accumetrics, Calypso Medical and Lutonix.

bottom of page